Armata Pharmaceuticals, Inc. (ARMP) financial statements (2022 and earlier)

Company profile

Business Address 4503 GLENCOE AVENUE
MARINA DEL REY, CA 90292
State of Incorp. WA
Fiscal Year End December 31
SIC 2836 - Biological Products, Except Diagnostic Substances (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in thousands)

12/31/2021
12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments10,2889,6496,0338,1575,1325,7119,370
Cash and cash equivalents10,2889,6496,0338,1575,1325,7119,370
Receivables     25125
Other undisclosed current assets4,7071,197622251253619521
Total current assets:14,99510,8466,6558,4085,3856,35510,016
Noncurrent Assets
Operating lease, right-of-use asset35,85210,7902,028
Property, plant and equipment2,2202,0472,1875038161,0721,131
Intangible assets, net (including goodwill)13,74613,74613,7462,7314,66110,46120,008
Goodwill3,4903,4903,490   7,562
Intangible assets, net (excluding goodwill)10,25610,25610,2562,7314,66110,46112,446
Restricted cash and investments1,2001,200700    
Other noncurrent assets1,755887135    
Other undisclosed noncurrent assets   245276307338
Total noncurrent assets:54,77328,67018,7963,4795,75311,84021,477
TOTAL ASSETS:69,76839,51625,45111,88711,13818,19531,493
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities, including:2,2701,9291,2782,5721,9681,6591,464
Accounts payable1,138956547729578  
Employee-related liabilities   1,3521,050895308
Interest and dividends payable   383838 
Other undisclosed accounts payable and accrued liabilities1,1329737314533027261,156
Debt  1,308  803 
Deferred compensation liability1,0355631,323    
Due to related parties      56
Business combination, contingent consideration, liability 1,940970    
Deferred revenue and credits  245
Other liabilities     185 
Other undisclosed current liabilities1,5092,273   933620
Total current liabilities:4,8146,7054,8792,5721,9683,5802,385
Noncurrent Liabilities
Long-term debt and lease obligation36,48010,8771,555    
Operating lease, liability36,48010,8771,555
Liabilities, other than long-term debt3,0773,0774,4248411,4394,8923,005
Deferred tax liabilities, net8191,1472,4493,005
Deferred income tax liabilities3,0773,0773,077
Business combination, contingent consideration, liability  1,347    
Derivative instruments and hedges, liabilities   222922,443 
Other undisclosed noncurrent liabilities      1,499
Total noncurrent liabilities:39,55713,9545,9798411,4394,8924,504
Total liabilities:44,37120,65910,8583,4133,4078,4726,889
Temporary equity, carrying amount      11,890
Stockholders' equity
Stockholders' equity attributable to parent25,39718,85714,5938,4747,7319,72312,714
Common stock271187993239516559
Additional paid in capital227,983198,372172,015414,467401,842390,918375,177
Accumulated deficit(202,857)(179,702)(157,521)(406,316)(394,206)(381,360)(362,522)
Total stockholders' equity:25,39718,85714,5938,4747,7319,72312,714
TOTAL LIABILITIES AND EQUITY:69,76839,51625,45111,88711,13818,19531,493

Income statement (P&L) ($ in thousands)

12/31/2021
12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
Revenues
(Revenue, Net)
    115260475
Gross profit:    115260475
Operating expenses(28,296)(22,410)(19,752)(12,524)(16,271)(23,638)(10,702)
Other undisclosed operating income4,474823     
Operating loss:(23,822)(21,587)(19,752)(12,524)(16,156)(23,378)(10,227)
Nonoperating income (expense)
(Other Nonoperating Income (Expense))
667(594)273862,0163,9849,638
Interest and debt expense(64)(628)(931)  (6) 
Other undisclosed income from continuing operations before equity method investments, income taxes 628931  6 
Loss from continuing operations before equity method investments, income taxes:(23,219)(22,181)(19,479)(12,438)(14,140)(19,394)(589)
Other undisclosed income from continuing operations before income taxes64      
Loss from continuing operations before income taxes:(23,155)(22,181)(19,479)(12,438)(14,140)(19,394)(589)
Income tax benefit   3281,30255673
Net loss attributable to parent:(23,155)(22,181)(19,479)(12,110)(12,838)(18,838)(516)
Preferred stock dividends and other adjustments     (1,858)(10,278)
Other undisclosed net loss available to common stockholders, basic     (3,580) 
Net loss available to common stockholders, basic:(23,155)(22,181)(19,479)(12,110)(12,838)(24,276)(10,794)
Other undisclosed net loss available to common stockholders, diluted  (938)(55)(1,524)  
Net loss available to common stockholders, diluted:(23,155)(22,181)(20,417)(12,165)(14,362)(24,276)(10,794)

Comprehensive Income ($ in thousands)

12/31/2021
12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
Net loss:(23,155)(22,181)(19,479)(12,110)(12,838)(18,838)(516)
Comprehensive loss, net of tax, attributable to parent:(23,155)(22,181)(19,479)(12,110)(12,838)(18,838)(516)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: